Expertise in
1
conditions

Mariusz Stasiolek

Rzgowska Str, 281/289, 
Lodz, LD, PL 
Expertise in
1
conditions
Rzgowska Str, 281/289, 
Lodz, LD, PL 
OverviewLocationsClinical Research

Overview

Mariusz Stasiolek practices in Lodz, Poland. Mr. Stasiolek is highly rated in 1 condition, according to our data. His top areas of expertise are Multiple Sclerosis (MS), Chronic Polyradiculoneuritis, Chronic Inflammatory Demyelinating Polyneuropathy, and Poland Syndrome.

His clinical research consists of co-authoring 56 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Rzgowska Str, 281/289, Lodz, LD 93338, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Biological
Study Drug: HYQVIA
Study Phase: Phase 3
A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® (CLARIFY MS)
A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® (CLARIFY MS)
Enrollment Status: Completed
Publish Date: September 14, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological
Study Drugs: HYQVIA, Intravenous Immunoglobulin G
Study Phase: Phase 3
View 2 Less Clinical Trials

56 Total Publications

Deep learning-based automatic segmentation of brain structures on MRI: A test-retest reproducibility analysis.
Deep learning-based automatic segmentation of brain structures on MRI: A test-retest reproducibility analysis.
Journal: Computational and structural biotechnology journal
Published: December 30, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Stasiolek's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile